#USA #Class Action #San Francisco #VYKAT XR #Soleno Therapeutics

Soleno Therapeutics Faces Legal Challenges Amid Drug Launch Troubles

Soleno Therapeutics, Inc., also known by its ticker symbol SLNO, has recently become the target of a securities class action lawsuit, which marks a significant turn of events for the company. The lawsuit aims to represent investors who acquired Soleno's common stock between March 26, 2025, and November 4, 2025. This legal action was triggered by the disappointing information released by the firm about its drug DCCR, recognized by its trademark VYKAT™ XR, which is aimed at treating hyperphagia associated with Prader-Willi Syndrome (PWS).

Background on DCCR and Hyperphagia

Prader-Willi Syndrome is a rare genetic disorder that leads to various physical, mental, and behavioral challenges, with hyperphagia described by Soleno as the most life-limiting issue associated with PWS. The drug DCCR, intended to provide relief from hyperphagia, encountered substantial backlash after Soleno made a public announcement on November 5, 2025, which resulted in a dramatic 26% plunge in the company's stock price.

Investor Concerns Alleviated

Following the release of the aforementioned report, Soleno has come under scrutiny, prompting Hagens Berman, a prominent national shareholder rights firm, to investigate potential violations of federal securities laws. The firm has encouraged investors who suffered significant losses during the mentioned class period to come forward. As of now, the lead plaintiff deadline for this class action is set for May 5, 2026.

Claims in the Lawsuit

The lawsuit emphasizes the company's repeated assertions concerning the safety, efficacy, and potential market success of DCCR. Executives had previously assured investors that the launch had exceeded expectations, claiming that everything was progressing optimally. However, allegations made in the lawsuit suggest that the Phase 3 clinical program for DCCR severely downplayed real safety concerns related to the drug, including the risk of excessive fluid retention among trial participants. Consequently, the regulatory status of DCCR poses risks that executives allegedly failed to accurately disclose.

Rising Alarm Over Drug Safety

Concerns about DCCR were amplified when short seller Scorpion Capital publicly criticized Soleno’s disclosures in August 2025. Scorpion raised alarms regarding an alarming increase in hospitalizations due to potential heart failure among children who had received the drug. These assertions brought forth significant questions regarding the integrity of Soleno's clinical trials and whether the metrics they presented were inflated.

Moreover, it was argued that Soleno depended heavily on a controversial physician linked to critical trials, leading observers to suspect that their reported success might not be as strong as claimed. Spurred on by these revelations, stock prices for Soleno have already dropped nearly 40% since the negative report was published.

Conclusion Amid Uncertain Future

The financial fallout stemming from these allegations poses a considerable headache for Soleno as it attempts to navigate the complicated waters of investor sentiment and public trust. Reed Kathrein, partner at Hagens Berman, is leading the investigation into these claims, emphasizing the importance of transparency and accountability from corporate actors.

Overall, this situation illustrates the complexities and challenges faced by biopharmaceutical companies in managing stakeholder relations amid product launches. Investors interested in pursuing recourse as part of the class action should act swiftly to submit their details to Hagens Berman, as the firm believes there could be significant ramifications for those misled by the company’s communications regarding the viability and safety of VYKAT™ XR.

For further information or inquiries into this case, investors are advised to visit Hagens Berman’s website or contact them directly.